Xue-Jiao Lv, Li-Jing Zhao, Yu-Qiu Hao, Zhen-Zhong Su, Jun-Yao Li, Yan-Wei Du, Jie Zhang
Lung cancer is the leading cause of cancer death in the world. Schizandrin B (Sch B) is one of the main dibenzocyclooctadiene lignans present in the fruit of Schisandra chinensis (Schisandraceae). Sch B has multiple functions against cancer. The aim of this study was to determine the effect of Sch B on the proliferation, cell cycling, apoptosis and invasion of lung adenocarcinoma A549 cells by MTT, flow cytometry, wound healing and transwell invasion assays. Treatment with Sch B inhibited the proliferation of A549 cells in a dose-dependent manner. Sch B induced cell cycle arrest at G0/G1 phase by down-regulating the expression of cyclin D1, cyclin-dependent kinase (CDK)4, and CDK6, but up-regulating p53 and p21 expression in A549 cells. Furthermore, Sch B triggered A549 cell apoptosis by increasing Bax, cleaved caspase-3, 9, Cyto C, but decreasing Bcl-2 and PCNA expression. In addition, Sch B inhibited the invasion and migration of A549 cells by down-regulating the expressions of HIF-1, VEGF, MMP-9 and MMP-2. Therefore, Sch B has potent anti-tumor activity and may be a promising traditional Chinese medicine for human lung carcinoma.
Exp Cell Res. 2014 Apr 1;322(2):415-24
[PMID:
24556425]
Cell Cycle. 2004 Apr;3(4):429-31
[PMID:
15020844]
Cell. 2004 Jan 23;116(2):221-34
[PMID:
14744433]
J Cell Mol Med. 2003 Jul-Sep;7(3):249-57
[PMID:
14594549]
Biol Pharm Bull. 2007 Jun;30(6):1108-12
[PMID:
17541162]
World J Biol Chem. 2014 Aug 26;5(3):355-76
[PMID:
25225603]
Angiogenesis. 2005;8(2):169-82
[PMID:
16211363]
Cancer Sci. 2003 Jan;94(1):15-21
[PMID:
12708468]
PLoS One. 2011;6(12 ):e28335
[PMID:
22164272]
Mol Cell Biochem. 2002 Sep;238(1-2):181-6
[PMID:
12349905]
Nat Rev Cancer. 2007 Oct;7(10 ):778-90
[PMID:
17882278]
Mol Cancer Ther. 2006 Sep;5(9):2149-57
[PMID:
16985047]
Eur J Cancer. 2010 May;46(7):1177-80
[PMID:
20307970]
Annu Rev Biochem. 2004;73:39-85
[PMID:
15189136]
Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6753-60
[PMID:
18006777]
Biol Pharm Bull. 2008 Jul;31(7):1387-91
[PMID:
18591780]
Expert Rev Mol Med. 2008 Jul 01;10:e19
[PMID:
18590585]
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6334-9
[PMID:
20308559]
PLoS One. 2012;7(7):e40480
[PMID:
22848381]
Cell Prolif. 2003 Jun;36(3):131-49
[PMID:
12814430]
Biomed Pharmacother. 2011 Jun;65(3):137-41
[PMID:
21612887]
CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71
[PMID:
24890451]
J Cell Physiol. 2009 Aug;220(2):292-6
[PMID:
19415697]
Cancer Cell Int. 2012 Nov 23;12(1):49
[PMID:
23176676]
Biochem Pharmacol. 2006 Feb 28;71(5):584-95
[PMID:
16405922]
Int J Cancer. 2004 Mar 20;109(2):189-93
[PMID:
14750168]
Oncogene. 2007 May 28;26(25):3745-57
[PMID:
17530027]
Crit Rev Oncol Hematol. 2006 Oct;60(1):59-75
[PMID:
16806960]
Surg Oncol Clin N Am. 2011 Oct;20(4):637-53
[PMID:
21986262]
Chin J Cancer Res. 2013 Jun;25(3):322-33
[PMID:
23825909]
Int J Mol Med. 2009 Oct;24(4):495-502
[PMID:
19724890]